StockData
AbbVie Inc. logo

AbbVie Inc.

ABBVNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 3, 2026Score 10/3094% above fair value
$288.84−6.05 (-2.05%)

Close on Nov 2, 2026Market cap $510.41BP/E 81.6Yield 2.30%

AbbVie Development and Regulatory Milestones Recognized in R&D by Year

Development and Regulatory Milestones Recognized in R&D ($M) ($M)

AbbVie Development and Regulatory Milestones Recognized in R&D: $208M in FY2025, up 60.0% from a year earlier.

Latest, FY2025
208
Period ended Dec 31, 2025
Change on a year earlier
+60.0%
130 in FY2024
History
6 years
Since FY2020
Sources
4
Documents cited below

Where the FY2025 figure comes from

Source: Form 10-K (filed 2026-02-20) ↗

Reported in Form 10-Q / 10-K Note 5 Licensing, Acquisitions & Other Arrangements.

Annual history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedDevelopment and Regulatory Milestones Recognized in R&D ($M) ($M)Year on yearSource
FY2025Dec 31, 2025208+60.0%Form 10-K (filed 2026-02-20) ↗
FY2024Dec 31, 2024130-33.7%Form 10-K (filed 2026-02-20) ↗
FY2023Dec 31, 2023196-22.2%Form 10-K (filed 2026-02-20) ↗
FY2022Dec 31, 2022252+55.6%Form 10-K (filed 2025-02-14) ↗
FY2021Dec 31, 2021162-9.0%Form 10-K (filed 2024-02-20) ↗
FY2020Dec 31, 2020178–Form 10-K (filed 2023-02-17) ↗

Cite this data

StockData. (2026). AbbVie Development and Regulatory Milestones Recognized in R&D ($M), annual FY2020–FY2025 [Data set]. Compiled from AbbVie SEC filings and investor materials. https://stockdatahq.com/stocks/abbv/kpis/iprd-milestones-exp

See every metric in the AbbVie KPI table. Data updated Oct 26, 2026.